The prospectuses/supplementary prospectuses/information memorandum/supplementary information memorandum are prepared strictly for information purposes only. It does not have regard to the specific investment objectives or the financial situation needs of any specific person who may receive it physically or virtually. Before investing you are advised to read and understand the contents of the Master Prospectus dated 1 April 2022, First Supplementary Master Prospectus dated 1 December 2022, the Prospectus of PMB-An-Nur Waqf Income Fund dated 18 March 2021, First Supplementary Prospectus of PMB-An-Nur Waqf Income Fund dated 1 December 2022, the Prospectus of PMB Shariah Global Equity Fund dated 15 October 2021, First Supplementary Prospectus of PMB Shariah Global Equity Fund dated 28 February 2023, the Prospectus of PMB Shariah Greater China Equity Fund dated 26 May 2022, and the Information Memorandum dated 5 May 2017, First Supplementary Information Memorandum for PMB Wholesale Sukuk Fund dated 31 December 2020 and Second Supplementary Information Memorandum for PMB Wholesale Sukuk Fund dated 1 August 2022 which all had been registered with the Securities Commission Malaysia, who takes no responsibility for its contents. All prospectuses/information memorandum (principal or supplementary) are obtainable from PMB Investment Head Office, any nearest PMB Investment Sales Offices, authorized unit trust consultants of PMB Investment or PMB Investment official website.
Any issue of units to which the prospectuses/information memorandum (principal or supplementary) relate to, will only be made on receipt of the application form referred to in and accompanying the Prospectuses. You should consider the fees and charges involved. The prices of units and distributions payable (if any) may go down as well as up. Past performance of the Funds are not indicative of its future performance. Investment in the unit trust funds are subject to various risks. Product Highlight Sheet (PHS) is also available and you have the right to request for it. The PHS and any other product disclosure document should be read and understood before making any investment decision.
If in doubt, please consult a professional adviser and investors may also call our Customer Service Careline at 03-4145 3900 for further assistance.
